Profil bibliographique

Oscar A. Gomez Vilamajo

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

10Publications signalées

807Citations signalées

0Affiliations récentes

Domaines associés

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsAtrial Fibrillation Management and OutcomesProtease and Inhibitor MechanismsCardiac Valve Diseases and Treatments

Publications récentes

Accès ouvert 2025 articleOpenAlex

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

Philippe Gabríel Steg, Michael Szarek, J. Wouter Jukema, Deepak L. Bhatt et autres

25 citationsCirculation

Accès ouvert 2024 articleOpenAlex

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

Shaun G. Goodman, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

24 citationsEuropean Heart Journal - Cardiovascular Pharmacotherapy

Accès ouvert 2024 articleOpenAlex

Blood Pressure and Intensive Treatment Up-Titration After Acute Heart Failure Hospitalization: Insights from the STRONG-HF Trial

Matteo Pagnesi, Oscar A. Gomez Vilamajo, Alejandro Meiriño, Carlos Dumont et autres

12 citationsEuropean Journal of Heart Failure

Accès ouvert 2022 articleOpenAlex

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

125 citationsCirculation

Accès ouvert 2021 articleOpenAlex

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo, Garen Manvelian et autres

144 citationsJournal of the American College of Cardiology

Accès ouvert 2021 articleOpenAlex

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner, Deepak L. Bhatt et autres

40 citationsDiabetes Care

Accès ouvert 2019 articleOpenAlex

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie T. Baccara‐Dinet et autres

331 citationsThe Lancet Diabetes & Endocrinology

Accès ouvert 2019 articleOpenAlex

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

Shinya Goto, Pantep Angchaisuksiri, Jean‐Pierre Bassand, A. John Camm et autres

55 citationsJournal of the American Heart Association

Accès ouvert 2018 articleOpenAlex

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

Jitendra PS. Sawhney, V A Kothiwale, Vikas Bisne, Rajashekhar Durgaprasad et autres

21 citationsIndian Heart Journal

2000 articleOpenAlex

Acute Cardiac Rupture During Dobutamine-Atropine Echocardiography Stress Test

André Domingo Oscar Orlandini, Enrique Tuero, Rafael Díaz, Oscar A. Gomez Vilamajo et autres

29 citationsJournal of the American Society of Echocardiography

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.